Read this before your intake. Your prescriber will assess all of this individually — but being informed helps you make the right decision for your health.
Based on established clinical guidelines, you may be a candidate for GLP-1 treatment if you meet one of the following:
Eligibility is determined by the reviewing prescriber. Meeting BMI criteria does not guarantee a prescription.
Personal or family history of medullary thyroid carcinoma (MTC). GLP-1 medications carry a boxed warning for this risk based on rodent studies.
Personal or family history of Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Do not use these medications.
Not for use during pregnancy, while attempting to become pregnant, or if breastfeeding. Discontinue at least 2 months before planned pregnancy.
Known allergic reaction or hypersensitivity to semaglutide, tirzepatide, or any component of the formulation.
Most side effects are GI-related and tend to improve after the first few weeks of treatment, especially with slow titration.
GLP-1 medications slow gastric emptying, which can affect how quickly other oral medications are absorbed. Always disclose your full medication list to your prescriber. Key interactions to discuss:
Store at 36–46°F (2–8°C). Do not freeze. Allow to reach room temperature before injection.
Keep in original packaging. Do not expose to direct sunlight or high temperatures.
Do not use after the expiration date. Discard any unused portion in an appropriate sharps container.
Your prescriber will review your specific health history before issuing any prescription.